The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.
 
Abraham C.F. Leung
Employment - Dynavax Technologies
 
Shivaani Kummar
Consulting or Advisory Role - Corvus Pharmaceuticals; MedTree (I)
Research Funding - Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Loxo (Inst); Pfizer (Inst)
 
Sanjiv S. Agarwala
No Relationships to Disclose
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca
Speakers' Bureau - Amgen; AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Baxalta; Takeda
 
Rene Gonzalez
No Relationships to Disclose
 
Joseph J. Drabick
Honoraria - Merck; Novartis
 
Emmett V. Schmidt
Employment - Merck
 
Elliot Chartash
Employment - Merck
 
Biao Xing
Employment - Dynavax Technologies
 
Graeme Currie
Employment - Dynavax Technologies
 
Robert Janssen
Employment - Dynavax Technologies
Leadership - Dynavax Technologies
Stock and Other Ownership Interests - Dynavax Technologies
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis